Page last updated: 2024-11-05

thalidomide and Hidradenitis Suppurativa

thalidomide has been researched along with Hidradenitis Suppurativa in 12 studies

Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.

Hidradenitis Suppurativa: A chronic suppurative and cicatricial disease of the apocrine glands occurring chiefly in the axillae in women and in the groin and anal regions in men. It is characterized by poral occlusion with secondary bacterial infection, evolving into abscesses which eventually rupture. As the disease becomes chronic, ulcers appear, sinus tracts enlarge, fistulas develop, and fibrosis and scarring become evident.

Research Excerpts

ExcerptRelevanceReference
"Treatment with apremilast has recently demonstrated clinically meaningful improvement in moderate hidradenitis suppurativa (HS)."9.30Apremilast for moderate hidradenitis suppurativa: no significant change in lesional skin inflammatory biomarkers. ( Davelaar, N; Mus, AMC; Prens, EP; van der Zee, HH; van Doorn, MBA; Vossen, ARJV, 2019)
"We report the "real-life" use of apremilast in the treatment of multimorbid patients with hidradenitis suppurativa and review its potential role in the management of this severe condition."9.05Apremilast for the treatment of hidradenitis suppurativa associated with psoriatic arthritis in multimorbid patients: Case report and review of literature. ( De Simone, C; Garcovich, S; Giovanardi, G; Malvaso, D; Peris, K, 2020)
"Effective anti-inflammatory treatments for hidradenitis suppurativa (HS) are limited."6.90Apremilast for moderate hidradenitis suppurativa: Results of a randomized controlled trial. ( Prens, EP; van der Zee, HH; van Doorn, MBA; Vossen, ARJV, 2019)
"Treatment with apremilast has recently demonstrated clinically meaningful improvement in moderate hidradenitis suppurativa (HS)."5.30Apremilast for moderate hidradenitis suppurativa: no significant change in lesional skin inflammatory biomarkers. ( Davelaar, N; Mus, AMC; Prens, EP; van der Zee, HH; van Doorn, MBA; Vossen, ARJV, 2019)
"We report the "real-life" use of apremilast in the treatment of multimorbid patients with hidradenitis suppurativa and review its potential role in the management of this severe condition."5.05Apremilast for the treatment of hidradenitis suppurativa associated with psoriatic arthritis in multimorbid patients: Case report and review of literature. ( De Simone, C; Garcovich, S; Giovanardi, G; Malvaso, D; Peris, K, 2020)
"Effective anti-inflammatory treatments for hidradenitis suppurativa (HS) are limited."2.90Apremilast for moderate hidradenitis suppurativa: Results of a randomized controlled trial. ( Prens, EP; van der Zee, HH; van Doorn, MBA; Vossen, ARJV, 2019)

Research

Studies (12)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's7 (58.33)24.3611
2020's5 (41.67)2.80

Authors

AuthorsStudies
Agud-Dios, M1
Arroyo-Andrés, J1
Rubio-Muñiz, C1
Postigo-Lorente, C1
Lanna, C1
Mazzilli, S1
Zangrilli, A1
Bianchi, L1
Campione, E1
Garcovich, S1
Giovanardi, G1
Malvaso, D1
De Simone, C1
Peris, K1
Proietti, I1
Michelini, S1
Mambrin, A1
Di Fraia, M1
Tolino, E1
Balduzzi, V1
Bernardini, N1
Marchesiello, A1
Porta, N1
Skroza, N1
Romeo, G1
Di Cristofano, C1
Petrozza, V1
Potenza, C1
Aarts, P2
Vossen, ARJV4
van der Zee, HH4
Prens, EP4
van Straalen, KR2
Dudink, K1
Ardon, CB1
Weber, P1
Seyed Jafari, SM1
Yawalkar, N1
Hunger, RE1
Davelaar, N1
Mus, AMC1
van Doorn, MBA2
Kerdel, FR1
Azevedo, FA1
Kerdel Don, C1
Don, FA1
Fabbrocini, G1
Kerdel, FA1
Hotz, C1
Sbidian, E1
Ingen-Housz-Oro, S1
Chosidow, O1
Wolkenstein, P1
Reddick, CL1
Singh, MN1
Chalmers, RJ1

Reviews

2 reviews available for thalidomide and Hidradenitis Suppurativa

ArticleYear
Apremilast for the treatment of hidradenitis suppurativa associated with psoriatic arthritis in multimorbid patients: Case report and review of literature.
    Medicine, 2020, Volume: 99, Issue:5

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Psoriatic; Hidradenitis Suppurativa; Human

2020
Clinical Implementation of Biologics and Small Molecules in the Treatment of Hidradenitis Suppurativa.
    Drugs, 2021, Volume: 81, Issue:12

    Topics: Adalimumab; Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Biological Products; CD40 Anti

2021

Trials

3 trials available for thalidomide and Hidradenitis Suppurativa

ArticleYear
Apremilast for moderate hidradenitis suppurativa: no significant change in lesional skin inflammatory biomarkers.
    Journal of the European Academy of Dermatology and Venereology : JEADV, 2019, Volume: 33, Issue:4

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antigens, CD; Antigens, Differentiation, T-Lymphocyt

2019
Apremilast for moderate hidradenitis suppurativa: Results of a randomized controlled trial.
    Journal of the American Academy of Dermatology, 2019, Volume: 80, Issue:1

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Double-Blind Method; Female; Hidradenitis Suppurativ

2019
Apremilast for the Treatment of Mild-to-Moderate Hidradenitis Suppurativa in a Prospective, Open-Label, Phase 2 Study
    Journal of drugs in dermatology : JDD, 2019, Feb-01, Volume: 18, Issue:2

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Female; Gastrointestinal Diseases; Hidradenitis Supp

2019

Other Studies

7 other studies available for thalidomide and Hidradenitis Suppurativa

ArticleYear
Successful treatment of hidradenitis suppurativa and Crohn's disease with combined guselkumab and apremilast.
    Dermatologic therapy, 2022, Volume: 35, Issue:10

    Topics: Antibodies, Monoclonal, Humanized; Crohn Disease; Hidradenitis Suppurativa; Humans; Thalidomide

2022
One drug and two diseases: A case of multidrug-resistant hidradenitis suppurativa and psoriasis treated with apremilast.
    Dermatologic therapy, 2019, Volume: 32, Issue:6

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Drug Resistance, Multiple; Hidradenitis Suppurativa; Humans

2019
A case of hidradenitis suppurativa successfully treated with apremilast in a patient with psoriasis and SAMPUS.
    Dermatologic therapy, 2020, Volume: 33, Issue:3

    Topics: Hidradenitis Suppurativa; Humans; Psoriasis; Thalidomide

2020
Long-term treatment with apremilast in hidradenitis suppurativa: A 2-year follow-up of initial responders.
    Journal of the American Academy of Dermatology, 2021, Volume: 85, Issue:1

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Duration of Therapy; Female; Follow-Up Studies; Hidr

2021
Apremilast in the treatment of moderate to severe hidradenitis suppurativa: A case series of 9 patients.
    Journal of the American Academy of Dermatology, 2017, Volume: 76, Issue:6

    Topics: Administration, Oral; Adult; Anti-Inflammatory Agents, Non-Steroidal; Dose-Response Relationship, Dr

2017
Thalidomide in Severe Hidradenitis Suppurativa: A Therapeutic Option.
    Acta dermato-venereologica, 2019, Nov-01, Volume: 99, Issue:12

    Topics: Adolescent; Adult; Female; Hidradenitis Suppurativa; Humans; Immunosuppressive Agents; Male; Remissi

2019
Successful treatment of superficial pyoderma gangrenosum associated with hidradenitis suppurativa with adalimumab.
    Dermatology online journal, 2010, Aug-15, Volume: 16, Issue:8

    Topics: Adalimumab; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Com

2010